177 related articles for article (PubMed ID: 11433422)
1. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
2. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.
Kumar A; Mikolajczyk SD; Goel AS; Millar LS; Saedi MS
Cancer Res; 1997 Aug; 57(15):3111-4. PubMed ID: 9242434
[TBL] [Abstract][Full Text] [Related]
3. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
Charlesworth MC; Young CY; Miller VM; Tindall DJ
J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
[TBL] [Abstract][Full Text] [Related]
4. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.
Lövgren J; Valtonen-André C; Marsal K; Lilja H; Lundwall A
J Androl; 1999; 20(3):348-55. PubMed ID: 10386814
[TBL] [Abstract][Full Text] [Related]
5. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
6. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Bridon DP; Dowell BL
Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
[TBL] [Abstract][Full Text] [Related]
7. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
8. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.
Villoutreix BO; Lilja H; Pettersson K; Lövgren T; Teleman O
Protein Sci; 1996 May; 5(5):836-51. PubMed ID: 8732755
[TBL] [Abstract][Full Text] [Related]
9. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
10. Expression of human glandular kallikrein, hK2, in mammalian cells.
Kumar A; Goel AS; Hill TM; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Saedi MS
Cancer Res; 1996 Dec; 56(23):5397-402. PubMed ID: 8968092
[TBL] [Abstract][Full Text] [Related]
11. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.
Deperthes D; Frenette G; Brillard-Bourdet M; Bourgeois L; Gauthier F; Tremblay RR; Dubé JY
J Androl; 1996; 17(6):659-65. PubMed ID: 9016396
[TBL] [Abstract][Full Text] [Related]
12. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase.
Takayama TK; McMullen BA; Nelson PS; Matsumura M; Fujikawa K
Biochemistry; 2001 Dec; 40(50):15341-8. PubMed ID: 11735417
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.
Takayama TK; Fujikawa K; Davie EW
J Biol Chem; 1997 Aug; 272(34):21582-8. PubMed ID: 9261179
[TBL] [Abstract][Full Text] [Related]
14. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
15. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
Hsieh ML; Charlesworth MC; Goodmanson M; Zhang S; Seay T; Klee GG; Tindall DJ; Young CY
Cancer Res; 1997 Jul; 57(13):2651-6. PubMed ID: 9205072
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
17. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2.
Mikolajczyk SD; Millar LS; Marker KM; Grauer LS; Goel A; Cass MM; Kumar A; Saedi MS
Eur J Biochem; 1997 Jun; 246(2):440-6. PubMed ID: 9208936
[TBL] [Abstract][Full Text] [Related]
18. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K
Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845
[TBL] [Abstract][Full Text] [Related]
19. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
20. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
